Family medicine clinicians prescribing GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists need to recognize telogen effluvium as a potential adverse effect to counsel patients about proactively, particularly given the high prevalence of these medications in weight loss and diabetes management. This adverse effect may influence medication selection, dosing strategy, or patient adherence discussions, especially in populations where hair loss carries significant psychosocial burden. Understanding the incidence and timeline of hair loss with semaglutide and tirzepatide allows clinicians to differentiate this medication-related effect from other causes of alopecia and manage patient expectations during therapy initiation.

A recent pharmacovigilance analysis examined the association between GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists with reports of hair loss submitted to the FDA Adverse Event Reporting System (FAERS). The study identified semaglutide and tirzepatide as demonstrating the highest reported rates of hair loss among the GLP-1 and GLP-1/GIP agonist class. These drugs, marketed under brand names including Ozempic, Wegovy, Mounjaro, and Zepbound, showed disproportionality signals when compared to other agents in their therapeutic class and when assessed against background reporting rates in the database.

The findings suggest that practitioners should counsel patients initiating semaglutide or tirzepatide about the potential risk of telogen effluvium or other forms of hair loss, particularly in patients with preexisting risk factors for alopecia. While hair loss is generally a non-serious adverse event, it can significantly impact patient quality of life and may influence medication adherence or continuation. The clinical relevance lies in informed consent and expectation-setting rather than avoidance of these agents, as semaglutide and tirzepatide remain first-line medications for their respective indications in weight management and glycemic control.

Prescribers should document discussions regarding this adverse event and remain attentive to patient reports of increased shedding, particularly within the first three to six months of therapy initiation. Patients who experience clinically significant hair loss may benefit from dermatology consultation and consideration of whether the hair loss represents a self-limited phenomenon related to rapid weight loss itself or a direct pharmacological effect requiring dose adjustment or medication discontinuation.

GLP-1 receptor agonists, particularly semaglutide and tirzepatide, have been associated with hair loss in clinical reports and observational data. This adverse effect likely relates to rapid weight loss triggering telogen effluvium, a temporary increase in shedding that occurs when hair follicles shift prematurely into the resting phase. The hair loss is typically reversible once weight stabilizes or the medication is discontinued, though recovery takes several months. When counseling patients starting GLP-1 therapy, proactively mention hair shedding as a known but generally temporary side effect, assess baseline hair health, and reassure patients that adequate protein intake and micronutrient repletion during weight loss may help minimize this cosmetic concern.

“What we’re seeing with semaglutide and tirzepatide is a manifestation of rapid weight loss itself rather than a direct drug toxicity, though the higher potency of these agents does accelerate the process. Telogen effluvium, the shedding pattern we observe, is fundamentally a nutritional stress response driven by caloric deficit and protein malnutrition, which means it’s largely preventable through adequate dietary protein intake and micronutrient optimization during treatment. I counsel every patient starting these medications that this is not a reason to discontinue therapy, but rather a signal to assess their nutritional status and ensure they’re consuming at least one gram of protein per kilogram of ideal body weight. The hair loss is temporary and reversible, but it’s a useful clinical marker that tells us whether a patient is losing weight in a metabolically healthy fashion or whether they’re experiencing excessive catabolism that requires dietary intervention.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: